ClinicalTrials.gg
CompletedNCT04440059Updated Apr 18, 2024

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

A Phase 2 interventional study of ICP-022 in Waldenstrom's Macroglobulinemia Recurrent and Waldenstrom's Macroglobulinemia Refractory, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2019, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Waldenstrom Macroglobulinemia with a site in China — 8 open to participants now, 12 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · China.

Enrollment
14th of 22
47 · median 65
Started
2019
with 1 other
Phase 2
8 of 22
3 open now
Registered
9th of 22
by date
Lead sponsor
1 of 22
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 22 studies in Waldenstrom Macroglobulinemia with a site in China, this one is the 14th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 9th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 62 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

8 of the 22 studies in Waldenstrom Macroglobulinemia with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Waldenstrom Macroglobulinemia studies recruiting now, 44 (92%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Waldenstrom Macroglobulinemia with a site in China, or all of them as a file.
02

Study summary

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

03

Conditions studied

  • Waldenstrom's Macroglobulinemia Recurrent
  • Waldenstrom's Macroglobulinemia Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  1. Clinical and confirmed giant globulinemia Fahrenheit (WM Ii International Working Group Standards, IWWM-2, 2003) (Owen et al., 2003)
  2. At least one treatment indication is met (7th WM International Working Group standards, IWWM-7) (Dimopoulos et al., 2014)
  3. With the lowest serum IgM value >2 times as the efficacy evaluation index
  4. physical strength score 0-2
  5. Voluntary written prior to trial screening.

Key Exclusion Criteria:

  1. Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or in the last 5 years
  2. Amyloidosis and central nervous system (CNS) involvement caused by WM
  3. Demonstrate disease transformation
  4. Patients who had received stem cell transplantation within the previous 6 months
  5. A history of organ transplantation or allogeneic bone marrow transplantation

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    ICP-022

    Subjects will take ICP-022 150mg once daily (QD).

    Drug: ICP-022

Interventions

  • ICP-022 at a dose of 150mg PO QD

06

What researchers measure

Primary outcomes

  1. Major response rate(MRR)

    Time frame: Up to 3 years

Secondary outcomes

  1. The occurrence of adverse events and serious adverse events

    The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria

    Time frame: Cycle 1 (every 2 weeks), cycle 2-12 (every 4 weeks); After cycle 12 (every 12 weeks). Each cycle is 28 days.

  2. Duration of Major Mitigation (DOMR)

    Time frame: Evaluate during the screening period, 1-6 treatment cycle every 2 cycles (8 weeks), 6th-27th cycles every 3 cycles, evaluating every 6 cycles after the 27th cycle. Each cycle is 28 days.

  3. Progression Free Survival (PFS)

    Time frame: Evaluate during the screening period, 1-6 treatment cycle every 2 cycles (8 weeks), 6th-27th cycles every 3 cycles, evaluating every 6 cycles after the 27th cycle. Each cycle is 28 days.

07

Study locations

16 sites
  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
    Hefei, Anhui, China
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100000, China
  • West China hospital of sichuan university
    Sichuan, Chengdu, China
  • Union Hospital affiliated to Fujian Medical University
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Henan Provincial Peoples's Hospital
    Zhengzhou, Henan, China
  • Tongji Hospital affiliated to Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning, China
  • Ruijin Hospital affiliated to Shanghai Jiao Tong University
    Shanghai, Shanghai, China
  • Hospital of Hematology, Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
  • Union Hospital affiliated to Huazhong University of Science and Technology
    Hubei, Wuhan, China
  • The First Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, Zhejiang, China
08

References and documents

Publications

  • Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, Liu T, Song YP, Xu B, Zhu ZM, Xu W, Zhang MZ, Tian YM, Zhang B, Zhao RB, Zhou DB. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 2022 Oct 4;52:101682. doi: 10.1016/j.eclinm.2022.101682. eCollection 2022 Oct. PubMed 36313145 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jan 2024, 52 months.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 52 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 19, 2020
StartActual
Aug 10, 2019
Primary completionActual
Jan 9, 2024
CompletionActual
Jan 9, 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04440059
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Aug 10, 2019
Primary completion
Jan 9, 2024
Completion
Jan 9, 2024
Last update
Apr 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion